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ARTICLE
Alternative splicing regulates stochastic
NLRP3 activity
Florian Hoss 1, James L. Mueller2, Francisca Rojas Ringeling 3, Juan F. Rodriguez-Alcazar1,
Rebecca Brinkschulte4, Gerald Seifert5, Rainer Stahl1, Lori Broderick2, Chris D. Putnam 2,6,
Richard D. Kolodner 2,6, Stefan Canzar 3, Matthias Geyer4, Hal M. Hoffman2,9 & Eicke Latz 1,7,8,9
Leucine-rich repeat (LRR) domains are evolutionarily conserved in proteins that function in
development and immunity. Here we report strict exonic modularity of LRR domains of
several human gene families, which is a precondition for alternative splicing (AS). We provide
evidence for AS of LRR domain within several Nod-like receptors, most prominently the
inﬂammasome sensor NLRP3. Human NLRP3, but not mouse NLRP3, is expressed as two
major isoforms, the full-length variant and a variant lacking exon 5. Moreover, NLRP3 AS is
stochastically regulated, with NLRP3 Δ exon 5 lacking the interaction surface for NEK7 and
hence loss of activity. Our data thus reveals unexpected regulatory roles of AS through
differential utilization of LRRs modules in vertebrate innate immunity.
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Innate immune cells rely on germ-line encoded signalingreceptors, so called pattern-recognition receptors (PRRs), tosense tissue dyshomeostasis induced by infection or caused by
metabolic defects and other injurious insults1,2. The interpreta-
tion of these physico-chemically diverse molecular cues by
immune cells is inﬂuenced and shaped by numerous mechanisms
including chemokine, cytokine, or G protein-coupled
receptors3–5. Innate immune cells must integrate those signals
and generate a tissue context adjusted inﬂammatory response
aimed at the destruction of microbes and repair of damaged
tissue, while preventing further damage caused by an inappro-
priately robust response.
NLR proteins have an especially wide spectrum of functions, as
they can act as cytosolic sensors of microbial molecules6, support
immune homeostasis in various tissues7, and play critical roles in
reproduction and embryogenesis8. Upon activation, some mem-
bers of the NLR family (e.g. NLRP3 and NLRC4) recruit multi-
protein signaling platforms, so called inﬂammasomes. NLRP3
consists of three functional domains, the N-terminal pyrin
domain (PYD), the NOD (also known as NACHT), and the C-
terminal LRR domain9. Inﬂammasome formation can be induced
by different receptors, however, they converge on the level of ASC
which serves as a platform for caspase-1 activation10. Active
caspase-1 cleaves pro-IL-1β and pro-IL-18 and induces the
release of their mature forms, which exert potent pro-
inﬂammatory effects11. Furthermore, the activation of caspase-1
results in an inﬂammatory type of cell death termed pyroptosis,
which requires gasdermin-D (GSDMD) cleavage12. NLRP3 is
triggered by asbestos, silica and other particular matter and is
involved in gout, atherosclerosis, and several neurodegenerative
diseases13. Due to its involvement in multiple diseases, NLRP3
has become one of the most studied PRRs. Nevertheless, the
molecular mechanisms of NLRP3 activation and regulation
remain only partially understood. A possible common upstream
activation mechanism involves potassium efﬂux from the cell14,15.
Yet, potassium-independent activators of the NLRP3 inﬂamma-
some were postulated as well16,17. Recently, the NIMA related
Kinase 7 (NEK7) was found to interact with NLRP3 as a pre-
condition of its activation18–20.
Another important, albeit less studied, mechanism of signaling
regulation is governed by alternative pre-mRNA splicing (AS).
During AS introns are removed and some protein coding exons
can be excluded from the assembled mature mRNAs allowing for
the generation of various mature mRNAs from the same DNA
template. AS can dramatically increase transcriptome complexity
and allows for the generation of various proteins from individual
genes with altered or distinct functions21. The proportion of
alternatively spliced genes has steadily increased during eukar-
yotic evolution suggesting that AS contributed to gain of orga-
nismal complexity during evolution. In humans, at least 95% of
multi-exonic genes undergo alternative splicing22 and AS is
particularly widespread in the nervous and immune systems23,24.
There is increasing evidence that AS contributes both to the
complexity of immune responses in various kingdoms25 and to
the development of various diseases26. Alternatively spliced pro-
teins can vary in their domain composition, sub-cellular locali-
zation or binding to ligands. Different isoforms can even act like
unrelated proteins and are frequently characterized by sig-
niﬁcantly different interaction proﬁles27. In the adaptive immune
system, different isoforms of CD45 and CD3ζ shape T-cell
activity24,28. While traditionally associated with adaptive immu-
nity, AS also provides mechanisms for PRR signaling. For
instance, a short isoform of MD-2 acts as a negative feed-back
regulator of TLR429.
Similar to other evolutionarily conserved PRRs, NLRP3 con-
tains structural elements that form a characteristic α/β horseshoe
fold consisting of leucine-rich repeats (LRR) motifs. LRR domains
are composed of repeating 20–30 amino acid stretches rich in
leucine, and each LRR unit typically contains a beta strand-turn-
alpha helix structure. LRR motifs confer the solenoid structure
and LRR domains provide the binding sites for a broad spectrum
of ligands, including proteins30, lipids31, nucleic acids32, and
bases33. Notably, the adaptive immune system of jawless verte-
brates lack the recombinatorial antigen receptors present in jawed
vertebrates, yet instead relies on lymphocyte receptors composed
of variable LRRs, which are assembled through somatic recom-
bination. Variable lymphocyte receptors (VLRs) represent the
adaptive arm of the immune system demonstrating the LRRs
versatility in interacting with a broad spectrum of molecular
entities34. In jawed vertebrates the LRR domain has a special role
in the regulation of NLR function. For example, crystallization of
the NLRC4 receptor showed that the LRR sequesters NLRC4 in
an auto-inhibited state and interacts with protein ligands35.
Similar mechanisms have been proposed for NLRP3 but have not
been conﬁrmed.
Here, we describe how AS of LRR genes drives the diversity of
PRRs and we analyze in detail how different NLRP3 isoforms
affect inﬂammasome activation. We identify that a prominent
splice form of NLRP3 cannot interact with NEK7 and therefore is
unable to form an inﬂammasome under conditions where the
full-length NLRP3 is fully functional. We propose that AS may
contribute to stochastic activatability of NLRP3 and suggest that
AS of LRRs in NLRs regulates human innate immune responses.
Results
Multiexonic organization of the LRR domain in the NLR
family. In TLRs, the majority of the LRR domain is encoded by a
long exon, which also encodes other functional units such as the
transmembrane and TIR domains. In contrast, the LRR domain
in NLR family members is typically encoded by multiple con-
secutive short exons, reminiscent of the short LRR encoding gene
segments found in the jawless vertebrate adaptive immune system
(Fig. 1a). We hypothesized that the characteristic exonic organi-
zation found in the LRRs of the NLR family might be conserved
in LRR encoding gene families and that differential splicing
within the LRR could contribute to functional diversity of enco-
ded proteins.
We performed a database analysis of all human genes
annotated to encode LRR domains and analyzed the length
distribution of the respective exons (Fig. 1b, c). Indeed, more than
half of all LRR encoding exons ranged between 75 and 200 bp,
which is the size range found in the LRR encoding exons of the
NLR family. A few exons picked up by the analysis are terminal
exons, which stretch far into the non-coding UTR of genes and
give only seemingly rise to large proteins. Exon skipping by AS
can lead to disruption of the original open reading frame, often
resulting in truncated protein products or nonsense-mediated
decay. We classiﬁed all detected exons smaller than 200 bp as
either frame-shifting or frame-preserving, and plotted exon
length versus their frequency. The vast majority was found to
be frame-preserving, suggesting that AS would also preserve
protein translation (Fig. 1d). Furthermore, exons with deﬁned
lengths that correspond to one or more LRRs of a typical length
(69–87 bp or 23–29 aa) were highly enriched, suggesting that an
exon-LRR structure relationship evolved (Fig. 1d). We identiﬁed
which genes contributed to the four major peaks of frame-
preserving exon length (Fig. 1e) and performed a phylogenetic
analysis on them (Fig. 1f). The peaks corresponded to distinct
gene families with conserved LRR exon structures, suggesting
conservation of exon structures compatible with AS of LRR
domains in several gene families.
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Fig. 1 LRR domains of the NLR family have a conserved multi-exon organization. a Scheme of domain and exon distribution in TLR4 and NLRP3. bWorkﬂow
for the selection of LRR exons used in c–f. c Length distribution of exons extracted in b. Box indicates 25th to 75th percentile, the middle line indicates the
median, whiskers indicate min and max values. d All exons up to 200 bp in length plotted for their frequency distribution. Exons were divided in frame-
shifting or frame-preserving. The typical length of LRRs (23 to 29 aa) is indicated as gray boxes. Colored boxes in the lower panel match assignment of
groups in the following subﬁgures. e Genes in word clouds represent those genes whose exons contribute to the respective peaks in d. Word size is linearly
dependent to the number of contributing exons. f Phylogenetic analysis of all genes contributing to the 4 major peaks in d. gModel of the NLRP3 LRR based
on the human ribonuclease inhibitor LRR crystal structure. h LRR consensus sequences and structural alignments for the four groups identiﬁed in d–f.
i Quantiﬁcation of all LLR exons vs. non-LRR exons of all NLRs which would be frame-shifting if alternatively spliced. Independence of distribution was
calculated using two-tailed Fischer’s exact test. See also Supplementary Fig. 1. Source data are provided as a Source Data ﬁle
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The high ligand diversity of the LRR-recombination based
jawless vertebrate adaptive immune system and the exonic
organization of the NLR LRRs might suggest a convergent
evolution of different classes of immune receptors. Therefore, we
focused our further analysis on the NLR LRRs, performed
structural alignments for all NLR LRRs and modeled the potential
structure of the NLRP3 LRR based on the human ribonuclease
inhibitor (RI) crystal structure (Fig. 1g). The NLRP3 LRR is
highly canonical. Every exon is exactly 171 bp long and encodes
two LRR, strictly alternating between 28 and 29 aa, resulting in
homogenous building blocks with a deﬁned surface curvature36.
Strikingly, the exon–exon border is always positioned at the exact
same position within the β-sheet, a characteristic that is
conserved across most NLRs. Most of them could be clearly
assigned in one of two classes only based on their exon structure.
The NLRP genes contain exons encoding two alternating LRRs of
28 and 29 aa, while most NOD and NLRC genes contain exons
that encode one LRR of 28 aa per exon (Fig. 1h, Supplementary
Fig 1a). This repetitive exon architecture is a necessary
precondition for the generation of functional isoforms by AS.
This is because the removal of one or several exons will produce a
shorter LRR domain likely without interfering with the overall
protein fold, as the hydrophobic residues forming the core of the
LRR scaffold are conserved. Moreover, the LRR exons of the NLR
proteins are strictly frame-preserving, while the large majority of
exons outside of the LRR region would lead to a frameshift if
alternatively spliced, indicating an evolutionary pressure to
maintain the spliceability of the LRRs (Fig. 1i). This exon-LRR
relationship is not only conserved within the NLR family but also
within the protein families containing the S/T (bacterial/typical)
class of LRRs (Fig. 1d–f, h). Together, this analysis implies that
differential splicing of LRR modules could create diverse protein
functions or could regulate the activity of human NLR family
members.
The splicing landscape of human NLRs. To analyze AS of
human NLRs we performed RNAseq on human monocyte-
derived macrophages (hMDMs) from ﬁve different donors. We
aimed for a sequencing depth of 200M paired-end reads per
donor to allow for a reliable detection of alternative splicing
events (for mapping summary see Supplementary Table 1). We
concentrated on RI-type LRR genes, which are comprised mostly
of NLRs. Prominent members of the NLR family are the
inﬂammasome activating receptors, NLRP1, NLRP3, and NLRC4.
However, NLRs are involved in diverse immune and non-
immune processes and by far not all of them are expressed in
macrophages. From all previously deﬁned RI-type LRR genes
(Fig. 1d–f), ribonuclease inhibitor (RNH1) was most highly
expressed, followed by NLRP3, NLRP1, NOD2, CIITA, NLRP2,
NOD1, and NLRP12 (Fig. 2a).
To monitor alternative splicing, we created sashimi plots for
those NLRs expressed in macrophages. Sashimi plots show the
read distribution along a gene locus and highlight exon-spanning
reads as arcs (Fig. 2b and Supplementary Fig. 2a–g). To allow for
reliable AS detection above splice noise, a high sequencing
coverage is important. Therefore, we focused on NLRP3 as the
most highly expressed NLR gene within this group.
Although AS events could be detected in all NLRs, the most
prominent AS within the LRR region was observed in NLRP3
(Fig. 2b and Supplementary Fig 2). To further characterize
NLRP3 splicing we calculated the exon inclusion levels (ψ=%
spliced in) for exon 5 and 7 using MISO (Fig. 2c, d). The narrow
conﬁdence intervals of the ψ histograms indicate a high level of
certainty for the inclusion frequency of the respective exon
according to the read distribution. It is evident that exon 5 is
consistently the most skipped exon (33%, 2.6% of exon 7), yet
minor splicing differences could be observed between donors.
Although exon-spanning reads allow for a qualitative analysis
of AS, a direct quantiﬁcation of exon spanning reads would only
be accurate for a perfectly uniform fragment distribution across a
gene. However, this is not achievable as evidenced by the unequal
read distribution within continuous long exons or intron-
spanning reads of consecutive exons.
The LRR domain of human NLRP3 undergoes alternative
splicing. After initial characterization of the splicing patterns of
the NLR gene family, we aimed to validate the RNAseq results
and to decipher whether differential splicing can affect the pro-
tein function of NLRP3. We thus PCR ampliﬁed the LRR region
of NLRP3 transcripts by using primers ﬂanking the LRR region
(Fig. 3a). While the ampliﬁed product from human cells ran as
double band on agarose gels, we were unable to detect any
alternative splicing of the LRR region of Nlrp3 in murine bone
marrow-derived macrophages or pig PBMCs (Fig. 3b). The size
difference of 171 bp between the two human amplicons corre-
sponds to the size of a single LRR exon. We characterized the
lower PCR band to encode for the greatest extend Δ exon 5
isoform (Supplementary Fig. 3a).
To conﬁrm the existence of a shorter splice variant of NLRP3
at the protein level, we next performed immunoprecipitation –
Western blot analysis on primary hMDMs and THP-1 cells
(Fig. 3c). To ensure that nonspeciﬁc Western blot bands are not
mistaken for an NLRP3 isoform, we performed immunoprecipi-
tations using an NLRP3 mAb targeted against the NACHT
domain and used a different mAb targeted against the NLRP3
PYD to visualize NLRP3. Of note, NLRP3 splicing in mouse
BMDMs was not detected at the RNA or protein level
(Supplementary Fig. 3b, c), and we thus conclude that AS of
NLRP3 is primarily found in human immune cells.
The described structural features of the NLRP3 LRR would
allow every LRR exon to be spliced out equally well. However, our
RNAseq and PCR analysis revealed a strong tendency for AS of
exon 5. Certain sequence elements can be associated with the
strength of a splice acceptor or donor site37. We used the
SplicePort algorithm tool to analyze the strength of splice donor
and acceptor sites in human NLRP3 pre-mRNA and identiﬁed
exon 5 acceptor followed by exon 7 acceptor as the least likely to
be used (Fig. 3d). Consistently, within the LRR of human NLRP3,
the fewest exonic splice enhancer sites (ESEs) were detected in
exon 5 using ESEﬁnder38 (Fig. 3e).
To analyze the prevalence of different isoforms more
accurately, we performed qPCR analysis using speciﬁc primers
for a given splice variant to minimize PCR bias of a long range
PCR. Besides the full-length variant and Δ exon 5, we probed as
well for Δ exon 7 and Δ exon 5/7 (Supplementary Fig. 3d), as the
most likely alternative splice events according to the SplicePort
scores (Fig. 3d) and our RNAseq data (Fig. 2). As expected,
the NLRP3 full-length variant was the major isoform and the
splice variant lacking exon 5 was the second most abundant,
while the isoforms lacking exon 7 and exon 5 and 7 were
expressed one and two magnitudes of order lower regardless of
the polarization state (M0, M1, and M2) of hMDMs (Supple-
mentary Fig. 3e).
NLRP3 Δ exon 5 is inactive. To analyze the function of the major
NLRP3 isoforms directly in primary human macrophages, we
made use of splice-switching oligos (SSOs) to direct the splicing
towards an increased percentage of NLRP3 Δ exon 5. SSO mor-
pholinos are nuclease-resistant DNA analogs39 designed
to complementarily bind to the intron-exon boundary of
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pre-mRNA. By blocking the spliceosome’s access to a speciﬁc
splice donor or acceptor site, the next possible respective site is
typically used, resulting in AS of the targeted exon (Fig. 3f).
Consistently, a SSO targeted to the intron 4 exon 5 boundary
yielded near reversal of the ratio of full-length NLRP3 to NLRP3
Δ exon 5 (Fig. 3g). hMDMs treated with a control morpholino
responded to NLRP3 activation, while cells treated with the SSO
released very low IL-1β amounts (Fig. 3h, left panel). Despite the
expected variance in the LPS response of hMDMs isolated from
different donors (data represent pooled data from several
donors), the SSO did not inhibit the priming or secretion of TNF
(Fig. 3h, right panel). Together, these data establish that splicing
of NLRP3 occurs in human macrophages and suggest that NLRP3
Δ exon 5 represents a loss-of-function isoform of NLRP3.
The relative high expression level of NLRP3 Δ exon 5 suggests
a deliberate isoform rather than splicing noise. To elucidate a
potential function of the splice variant independent of the full-
length variant, we made use of different model systems. HEK cells
lack expression of NLRP3 inﬂammasome components and can
thus be used as a minimalistic cellular environment to test the
intrinsic activity of NLRP3 independent of most regulatory
effectors. We reconstituted the respective NLRP3 isoforms and
ASC as ﬂuorescently tagged versions (encoded on a single
plasmid) and established cell lines using Flp-In technology in
HEK TREx cells (Fig. 4a). Since overexpression of NLRP3 is
sufﬁcient to cause activation in HEK cells, we made use of the
tetracycline inducible expression system. Doxycycline dose-
dependently induced overexpression of both isoforms of NLRP3
(Fig. 4b). However, overexpression led to activation of the full-
length but not the Δ exon 5 NLRP3 variant (Fig. 4c, d). Similarly,
when these NLRP3 expressing HEK cells were activated using
nigericin, we observed ASC speck formation only in cells
expressing the full-length but not the Δ exon 5 version of NLRP3
(Fig. 4e). We further tested whether the lack of response in the
Δ exon 5 NLRP3 variant is also observed at the level of ASC
polymerization, or whether the interaction of ASC and NLRP3 is
disturbed. Co-IPs of NLRP3 and ASC showed that the isoform
Δ exon 5 failed to interact with ASC, whereas full-length NLRP3
could co-immunoprecipitate ASC as expected (Fig. 4f).
To analyze the NLRP3 isoforms in the context of naturally
inﬂammasome competent cells, we made use of NLRP3-deﬁcient
immortalized macrophages (iMos), which we virally reconstituted
with either full-length NLRP3 or NLRP3 Δ exon 5 (Supplemen-
tary Fig. 4a). Cells were primed with LPS and either treated with
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NLRP3 speciﬁc activators or as control with stimuli of the NLRP1
or AIM2 inﬂammasome. Only NLRP3 full-length and not
NLRP3 Δ exon 5 reconstituted cells were able to mount an
NLRP3 speciﬁc inﬂammasome response (Fig. 4g), while all cell
lines showed comparable amounts of TNF secretion after LPS
priming and were fully capable to secrete IL-1β after activation of
the NLRP1 or AIM2 inﬂammasome, excluding any general
defects in the inﬂammasome pathway (Fig. 4g). Consistently,
iMos reconstituted with NLRP3 Δ exon 5 were neither capable of
producing the mature form of IL-1β nor could they cleave pro-
caspase-1 upon NLRP3 activation as shown by western blot
(Fig. 4h). Likewise, IL-1β secretion after activation of the non-
canonical inﬂammasome and after potassium-independent acti-
vation of NLRP3 could only be detected for NLRP3 full-length
expressing cells (Supplementary Fig. 4b–d).
Stochasticity of NLRP3 splicing. Splicing can be regulated on
single cell level, resulting in sub-populations of cells expressing
either one, several or neither isoform. We hypothesized, that AS
of NLRP3 might result in a sub-pool of cells with different acti-
vation characteristics. We primed hMDMs with LPS to induce
NLRP3 expression and analyzed NLRP3 full-length and NLRP3 Δ
exon 5 expression by single cell PCR. We analyzed 187 to
192 single cells of three independent donors for their expression
of NLRP3 full-length, NLRP3 Δ exon 5, HPRT, and 18S rRNA.
Although a fraction of cells expressed both splice variants, the
majority of cells expressed only one of the splice variants or did
not show NLRP3 mRNA expression at all (Fig. 5a, b). Due to the
intrinsic properties of gene expression on single cell level,
underlying a burst kinetic, the detected expression level of a gene
in a single cell cannot be interpreted as the transcriptome of bulk
cells (Fig. 5c). Although the concentration of protein products is
kept relatively stable, mRNA levels are highly ﬂuctuating. Upon
opening of a gene locus, the mRNA content is rapidly increased
and slowly declines to a minimum followed by the next peak
(Fig. 5c). Since these expression bursts are not synchronized in a
pool of cells, bulk RNA shows a stable expression mean at all
times, which can serve as a good indicator for the protein pro-
duct. 18S rRNA can be considered as an exception, as it is
expressed several magnitudes higher and the functional unit is the
RNA and not a protein product and therefore kept stable.
Therefore, we used 18S rRNA, instead of HPRT, as a measure to
control for technical dropouts but did not calculate any relative
expression levels (Fig. 5a, b). This analysis demonstrates that
NLRP3 splicing is likely not deterministic as we detected cells
expressing both NLRP3 full-length and NLRP3 Δ exon 5 at the
same time. Stochasticity in gene transcription inﬂuences
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variability of cell responses as single cells can behave differently
depending on the expression level of any given gene. This analysis
further demonstrates that there is large interindividual variability
regarding expression of NLRP3 in single cells.
To assess whether the stochastic expression of NLRP3 might
contribute to an adjustable response of cells to danger signals, we
evaluated whether AS of NLRP3 can affect the number of cells
responsive to NLRP3 triggers. We made use of two independent
assays to analyze the activation of single cells after inﬂammasome
activation in hMDMs. First, we evaluated the percentage of cells
forming an inﬂammasome speck upon NLRP3 or NLRC4
activation (Fig. 5d). Surprisingly, and in contrast to mouse
macrophages (Supplementary Fig. 5a), only a minor fraction of
hMDMs responded to NLRP3 stimuli. In contrast, nearly all
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hMDMs responded on a NLRC4 trigger, showing that inﬂamma-
some activation is achievable in these cells. Noteworthy, a decent
IL-1β response could still be detected after NLRP3 activation
(Supplementary Fig. 5b). To rule out a suboptimal activation of
the human cells by nigericin we tested increasing concentrations
and prolonged activation times (Fig. 5d, Supplementary Fig. 5c).
To test how many cells contribute to the IL-1β secretion, we
performed ELISpot assays, which measure IL-1β release from
single cells. Analogous to the ASC speck assays, only a minor
fraction of hMDMs contributed to the IL-1β release downstream
of NLRP3, while nearly all cells reacted upon triggering the
NLRC4 inﬂammasome (Fig. 5e), providing evidence for the
functional presence of all mutual inﬂammasome components.
Together, these results suggest that the NLRP3 inﬂammasome in
human macrophages is regulated on many levels, likely including
the level of gene expression and AS.
NLRP3 Δ exon 5 lacks the interaction surface for NEK7. NEK7
binding to NLRP3 was demonstrated as a prerequisite for NLRP3
activation and the NLRP3 binding site was suggested to be located
within the LRR18, yet the exact area of NEK7 binding on NLRP3
has not been identiﬁed. Therefore, we performed interaction
studies between the different NLRP3 isoforms and NEK7 using
iMo cell lines. Co-immunoprecipitation of NLRP3 demonstrated
an interaction of NLRP3 with endogenous NEK7 for the full-
length isoform but not for the NLRP3 Δ exon 5 isoform (Fig. 6a,
Supplementary Fig. 6a).
Next, we wondered whether the NLRP3 Δ exon 5 isoform
might be inactive as a result of a shorter LRR. An alternative
hypothesis was that the amino acids encoded by exon 5 are
speciﬁcally needed for the activation. To address these questions
we created an artiﬁcial NLRP3 version encoding a duplication of
exon 6 but no exon 5, so that the total LRR length was conserved.
We further created an NLRP3 version, in which exon 6 was
duplicated, but in the duplicated exon 6 all surface deﬁning
amino acids were revised to the exon 5 amino acids (Fig. 6b). Due
to the high level of conservation of the LRR exons, the overall
physico-chemical characteristics of the hybrid isoforms is similar
to the wildtype (wt) isoforms (Supplementary Table 2). Stable
iMo cell lines were created as before and the cells were primed
with LPS followed by NLRP3, AIM2, or NLRC4 activation.
Although AIM2 and NLRC4 activation resulted in comparable
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levels of IL-1β secretion across all tested cell lines, IL-1β secretion
could not be observed after NLRP3 activation in the NLRP3-
deﬁcient cells and in those reconstituted with the doubled exon 6.
However, iMos expressing the NLRP3 variant with a doubled
exon 6 but all surface amino acids of exon 5 in the ﬁrst two
repeats, were fully active (Fig. 6c). All cells were properly primed
as evidenced by comparable levels of TNF secretion (Supple-
mentary Fig. 6b).
Again, we performed co-IPs and tested the ability of all NLRP3
variants to interact with NEK7. While the duplicate exon 6 could
not interact with NEK7, the NLRP3 variant with a duplicated
exon 6 but a surface rescued to exon 5 showed a partial rescue of
the interaction with NLRP3 in iMos (Fig. 6d). Although this
partial rescue seems to be sufﬁcient to allow for full inﬂamma-
some activation, we tested whether the interaction is fully
recovered in a system in which human NLRP3 interacts with
human NEK7. Indeed, performing the same experiment after
transient transfection of HEK cells with NLRP3 variants
demonstrated a full rescue of the NLRP3-NEK7 interaction as
soon as all exon 5 surface amino acids were expressed (Fig. 6e).
Taken together, our data show that NEK7 binds to the LRRs
encoded by exon 5 of NLRP3.
Discussion
Except for the highly variable receptors involved in adaptive
immune response, every nucleated cell carries the same genetic
information. Genes encode for proteins and regulatory RNAs and
their coordinated expression determines cell identity and func-
tion. Functional diversity of proteins can be considerably
increased by AS, which is much more abundant in higher than in
lower eukaryotes. Although different species such as nematodes,
mice, and humans carry approximately the same amount of
protein coding genes (~20,000), they express about 50,000,
100,000, and 200,000 different isoforms, respectively. Accord-
ingly, the increased complexity is mostly achieved by a more
diverse AS pattern, not by more coding genes. As proteins are key
molecules that coordinate nearly all cellular functions, AS can
dramatically inﬂuence cell identity and cell speciﬁc functions40.
Although the higher prevalence of AS in humans compared to
mice is known, a gene-speciﬁc prediction of its impact is difﬁcult.
It is conceivable that the rather detrimental NLRP3 activity
associated with higher age of humans requires a higher level of
regulation than in lower species, where communicable diseases
represent the higher health thread. This would be in line with
other regulatory factors like pyrin- or CARD-only proteins,
shaping the human, but not murine inﬂammasome response10.
Around 500 million years ago, diversiﬁcation of the adaptive
immune system was achieved with the evolution of two different
recombinatorial approaches in vertebrates. In jawed vertebrates
the protein diversity of the immunoglobulin domain-based T and
B cell antigen receptors is achieved through somatic rearrange-
ment of V(D)J gene segments and hypermutation, while in jaw-
less vertebrates, somatic recombination of LRR sequences evolved
to create diversity in VLRs34. Hence, alternative LRR splicing
could represent (by the use of different means than VLRs) a
further level of increased functional diversity in the innate
immune system. Of note, the here detected exons, mostly
encoding for blocks of 24 or 28/29 aa, represent LRR modules of
self-compatible building blocks to create well folded protein
structures when repeatedly stacked36.
As in NLRs, domain boundaries and exon junctions in the
majority of genes show consistent strong correlations, which
further increases from invertebrates towards higher vertebrates41.
This not only allows for genomic exon re-shufﬂing42, but also
facilitates recombination or deletion of functional units by AS. Of
interest, in the plant immune system, AS of resistance genes has
evolved to regulate the immune response to pathogens and
stress43,44. Given the structural and functional homology of plant
resistance proteins and vertebrate NLRs, our ﬁndings solidify the
importance of this mechanism. Interestingly, inﬂammasome
responsiveness can also be modulated via differential splicing of
ASC, a mechanism tuning the responsiveness of cells for several
different inﬂammasome sensors. ASC-b lacks the ﬂexible inter
domain linker, reducing the efﬁciency of ASC speck formation,
and ASC-c lacks most of the PYD and inhibits IL-1β maturation
via a competitive mechanism45. Furthermore, human NLRP3
mRNA can be alternatively polyadenylated, resulting in a shor-
tened 3′UTR, which lacks binding site for the negative regulators
miRNA-223 and tristetraprolin46.
Although long recognized, the role for alternative splicing
among the sensor proteins was not well understood. We noted
multiple splice variants in our initial description of NLRP347.
NLRP3 isoforms lacking exon 5, or 5/7 were later tested for their
NF-kB suppressive properties, with no effect identiﬁed48. By
performing single-cell analysis of NLRP3 splicing of exon 5, we
have identiﬁed that NLRP3 splicing is likely not deterministic as
we could identify cells expressing both the full-length NLRP3
isoform as well as the isoform lacking exon 5. Although this
analysis cannot rule out that individual cells might be in the
process of shifting from expressing only one splice form to
expressing another splice form, it is tempting to speculate that AS
of NLRP3 contributes to the stochastic nature of NLRP3 acti-
vatability. The stochasticity of the inﬂammasome response causes
stimulated cells to exhibit large variability in their response to
danger signals. As the NLRP3 inﬂammasome is highly regulated
by many feed-forward as well as negative feed-back loops, sto-
chasticity would allow for ﬁne-tuning of a graded response that is
adjusted to the type and magnitude of danger molecules recog-
nized by NLRP3. At the same time, different activation thresholds
of NLRP3 could be important to prevent a coordinated pyroptotic
cell death of macrophages during the presence of danger signals,
which could subject the host to increased susceptibility for
infections. If the NLRP3 LRR acts as a self-inhibiting domain, as
shown for NLRC435, NEK7 might stabilize an activatable state
rather than causing activation. Indeed, a nonsense mutation in
NLRP3 exon 4 (R554X) results in the complete loss of the LRR
and the patient presents an inﬂammatory FMF/FCAS-like phe-
notype49, suggesting that self-inhibition of NLRP3 is lost.
Moreover, it was shown that an artiﬁcial NLRP3 variant lacking
the LRR could still be activated50.
Our bioinformatics analysis showed that NLR proteins share
the modularity of exons encoding for LRRs with several protein
families that carry short repetitive LRR encoding exons of the RI
and S/T class of LRRs, including Slit proteins involved in neu-
ronal axon guidance. A large heterogeneity of Slit mRNA could be
identiﬁed, and their binding properties are suggested to depend
on varying number of LRR repeat units51,52. LRRC37 was
restricted to the testis, but rapidly evolved in the hominid lineage
with higher levels of expression in the cerebellum and thymus
and increasing diversity of alternative splice forms53. Hence, AS
of LRR encoding exons appears to be a mechanism to create
functional diversity not only in the immune system.
General deﬁciencies in the splicing machinery are not com-
patible with life and gene-speciﬁc alternations in AS can result in
diseases and organ failures54. Cancer, cardiovascular diseases,
diabetes and neurological diseases have each been correlated with
speciﬁc changes in AS54. Consequently, several approaches have
been developed to correct disease-associated aberrant splicing or
to correct the reading frame after exon duplications or deletions.
Two SSO drugs have been recently approved to treat Duchenne
muscular dystrophy and spinal muscular atrophy55,56. Our
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studies suggest that using SSOs to induce the skipping of NLRP3
exon 5 in NLRP3-driven diseases might hold therapeutic poten-
tial in diseases associated with increased activity of NLRP3.
Methods
Isolation of primary cells, plasmids, and cell lines. Primary human and pig cells
were isolated from blood using ﬁcoll gradient centrifugation to obtain PBMCs.
Human monocytes were isolated from PBMCs with CD14 microbeads (Milteny)
according to the manufacture’s instruction. Macrophages were differentiated from
monocytes by incubation with rhGM-CSF (500U/mL) for 3 days. M1 macrophages
were further differentiated for three additional days with IFNγ (200U/mL) and GM-
CSF (500 U/mL), M2 macrophages with IL-4 (1000 U/mL) and GM-CSF (500U/mL).
Medium for all human cells is complete RPMI with 10% FCS, Glutamax, Na-Pyruvate
and Penicillin/Streptomycin (all three 100x stocks from Thermo-Fischer).
Mouse bone marrow-derived macrophages (BMDMs) were obtained by
culturing bone marrow cells from WT C57BL/6 mice in DMEM supplemented
with 10% fetal calf serum (FCS) and 20% L929 conditioned medium. Immortalized
NLRP3-deﬁcient mouse macrophages (iMos) were previously described57. HEK
cells and iMos were cultured in DMEM with 10% FCS and 100 U/mL penicillin/
streptomycin. The HEK293-FlpIn TREx cell line (Invitrogen) was used to create
cell lines with a single insertion of a single copy of the genes of interest. NLRP3-
deﬁcient iMos were retrovirally transduced with constructs for the indicated
NLRP3 variants fused C-terminally to an mCitrine-tag. After retroviral
transduction, cells were ﬂow cytometrically sorted to similar levels of expression
(Supplementary Fig. 7).
All plasmids were obtained using standard cloning techniques. The protein
sequence of NLRP3 2x Exon 6 surface rescue is as shown in Supplementary Note 1.
RNA isolation, NLRP3 LRR PCR and qPCR. RNA was isolated using the RNeasy
kit from Quiagen, according to the manufactures instructions. RNA (250–1000 ng)
were used to reverse-transcribe cDNA using an oligo dT(18) primer and Super-
Script III reverse transcriptase (Invitrogen).
Whole LRR PCR was performed on cDNA with EconoTaq PLUS GREEN 2x
mastermix from Lucigen using primers outside of the highly conserved LRR region.
To minimize any PCR bias towards possible smaller isoforms the elongation phase
of each cycle was set to 3 min. The primers used were the following: for human, P1
and P2;, for mouse, P3 and P4; for pig, P5 and P6.
cDNA abundance was analyzed using Maxima, SYBR Green/ROX qPCR Master
Mix from ThermoFischer on a QuantStudio6 cycler. The primers used were the
following: for HPRT, P7 and P8; for NLRP3 Exon 4–5, P9; for NLRP3 exon 5–6,
P10; for NLRP3 exon 4–6, P11; for NLRP3 exon 6–7, P12; for NLRP3 exon 6–8,
P13; and for NLRP3 exon 6, P14. All primer sequences are shown in
Supplementary Table 3.
Single-cell PCR. hMDMs were primed with 2 ng/mL LPS for 3 h. Single cells were
sorted into 96-well plates. Cells were lysed, RNA was reverse transcribed and
preampliﬁcation for NLRP3 variants and HPRT was performed for 20 cycles
(AmpliTaq Gold, Thermoﬁscher), before cDNA was split up for the detection of
different transcripts by TaqMan PCR. 18S RNA was not pre-ampliﬁed. Primers for
preampliﬁcation were: for NLRP3, P15 and P16; for NLRP3 Δexon 5, P17 and P18;
for HPRT, P19 and P20. Taqman assays were from Thermo Fischer (HPRT
HS02800695, 18S HS99999901_s1) or self-designed (labeled with 6-
carboxyﬂuorescein (6-FAM) on their 5′ end and a non-ﬂuorescent black hole
quencher (BHQ-1) on their 3′-end, Metabion) NLRP3 (primers P21 and P22,
probe: aacgctccagcatcctggctgtaaca) NLRP3 Δ exon 5 (primers P23 and P24, probe:
ttctcatgggttggggc). Reaction mix was GoTaq Probe qPCR Master mix (Promega).
All primer sequences are shown in Supplementary Table 3.
Sequencing of isoforms. The lower band lacking at least one exon was cut from
the gel, the PCR fragment was isolated and blunt ligated into a plasmid (CloneJET
PCR Cloning Kit, ThermoFischer), Bacteria were transformed and single clones
were picked. Minipreps of single clones were performed and DNA was sent for
sanger sequencing at GATC58.
Stimulation conditions. iMos were primed with 200 ng/mL LPS (Ultrapure LPS,
Invivogen) for 3 h. Inﬂammasome activation was performed with 10 µM nigericin
(Life Technologies) and 5mM ATP (Sigma) for 1 h or with 1mg/mL Silica (US-Silica),
1 mM LeuLeuoMe (ChemImpex), lethal toxin (1 µg/mL lethal factor (List Biologicals),
1 µg/mL, protective antigen (List Biologicals), poly(dA:dT) (20 ng/mL+ 0.5% lipo-
fectamin 2000), LFn-PrgI (4 µg/mL (M. Geyer)+ protective antigen 1 µg/mL) for 3 to
4 h, 12 or 25 µg/mL PGN from S. Aureus (Invivogen) for 20 h, 20 µg/mL R837
(Invivogen) for 1.5 h, cytosolic LPS (Cholera toxin subunit B (CTB) (20 μg/mL+
2 μg/mL LPS), or with DOTAP (3.75 μg/mL+ 750 ng/mL LPS)) for 16 h.
iMos for activated NLRP3-NEK7 Co-IP were primed with 200 ng/mL LPS for
2 h. CRID3 (Pﬁzer) was added for the last h and caspase inhibitor YVAD was
added 20 min before nigericin to prevent pyroptosis. Cells were activated with
10 µM nigericin for 20 min.
hMDMs were primed with 2 ng/mL LPS for 3 h and activated with 10 µM
nigericin for 1 h or LFn-PrgI (3 ng/mL)+ protective antigen 1 µg/mL) for 1 h.
Cytokine measurement. Secreted cytokines were measured by ELISA or HTRF
according to manufactures instructions (ELISA kits for mouse IL-1β and mouse
TNFα from R&D Systems, HTRF kits for mouse and human IL-1β and TNFα from
Cisbio).
ELISpot assays were performed using the hIL-1β kit from abcam according to
the manufacturer’s recommendations. To assure enough distance between single
cells and to allow for single spot discrimination, 300 hMDMs were seeded per
96 well.
Immunprecipitation. Cells were washed with PBS and lysed in RIPA buffer or Co-
IP lysis buffer (50 mM Tris pH 7.8, 50 mM NaCl, 0.1% NP-40, 10 % Glycerol,
cOmplete protease inhibitor and PhosSTOP (Roche), PMSF (0.2 mM). Nuclei were
removed by centrifugation (10 min, 1000×g) and protein concentration was nor-
malized after measurement by bichinonic acid assay (BCA; Thermo Fisher
Scientiﬁc).
Endogenous NLRP3 was immunprecipitated using an NLRP3 antibody
(D4D8T, Cell signaling) bound to protein G Dynabeads (Life Technologies). IP was
performed for 4 h at 4 °C. Samples were denatured with LDS buffer supplemented
with reducing agent (Thermo Fisher) for 10 min at 85 °C.
Co-immunprecipitation of NLRP3-mCitrine was perfomed in GFP-trap plates
(Chromotec) for 2.5 h at 4 °C shaking or using a tRFP antibody (AB233, evrogen)
coupled to protein G Dynabeads. Samples were denatured as described before.
Sample preparation and Immunoblots. Samples were prepared and immunoblots
performed as described before58. In brief, cells were washed with PBS and lysed
with NP-40 buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1%
Nonidet P-40, 10% glycerol, cOmplete protease, and PhosSTOP (Roche) inhibitor).
Nuclei were removed by centrifugation (10 min, 1000×g) and protein concentra-
tion was normalized after measurement with a bichinonic acid assay (BCA;
Thermo Fisher Scientiﬁc). Samples were reduced and denatured by adding
NuPAGE LDS Sample Buffer (4×) and NuPAGE Sample Reducing Agent (10×)
(both from Thermo Fisher) and heating at 85 °C for 10 min. Proteins were sepa-
rated by 4–12% SDS-PAGE in precast gels (Novex; Invitrogen) with MOPS buffer
(Novex; Invitrogen). Proteins were transferred onto Immobilon-FL PVDF mem-
branes (Millipore) and nonspeciﬁc binding was blocked with 3% BSA in Tris-
buffered saline for 1 h, followed by overnight incubation with speciﬁc primary
antibodies in 3% BSA in Tris-buffered saline with 0.1% Tween-20.
The following antibodies were used: NLRP3 (cryo2, AG-20B-0014-C100,
Adipogen; D4D8T, 151015, Cell Signaling) both 1:2000; β-actin (Licor) mouse
(926–42212) or rabbit (926–42210), both 1:1000; caspase-1 p10 (M20, sc-514,
SantaCruz) 1:200; IL-1β p17 (detection AB from R&D mouse ELISA Kit no.
840169) 1:1000; NEK7 (EPR4900, ab133514, Abcam) 1:500–1:2000; ASC (AL177,
210–905-C100, Adipogen) 1:1000; secondary antibodies (coupled to IRDye 800CW
or IRDye 680RD LI-COR Biosciences) 1:25000.
Splice-switching oligos. Morpholinos and Endo-porter were obtained from gene-
tools.com. Day 3 differentiated hMDMs were seeded with GM-CSF (250 U/mL) in
complete medium and were allowed to settle down before transfection. Morpho-
linos have been heated up to 65 °C before use to recover full activity. Morpholinos
and Endo-porter have been premixed and were carefully added to the cells to a ﬁnal
concentration of 6 µM each. Cells were LPS primed at 39 h after transfection.
Structural alignments and modeling of the NLRP3 LRR. Structural alignment of
LRRs was performed using the RI class (LxxLxLxx(N/C)xLxxxgoxxLxxoLxzxxxx)
or S/T class (LxxLxLxxNxLxxLpxxoFxzxLxx) consensus sequence.
Structural modeling was performed using SwissModel. The crystal structure of
human ribonuclease inhibitor (PDB: 2q4g) was used as a template.
ASC Speck analysis. HEK293-FlpIn TREx cells were treated overnight with the
indicated doses of doxycycline or stimulated with 10 µM and respective lower doses
of nigericin for 2.5 h. hMDMS were primed with LPS. 30 min before activation, the
caspase-1 inhibitor VX-765 was added at a ﬁnal concentration of 10 µM before cells
were activated for 1.5 h. Caspase-1 deﬁcient iMos were primed with LPS and
activated with nigericin.
HEK293-FlpIn TREx cells were ﬁxed with 2% formaldhyde and nuclei were
stained with Draq5 (eBioscience, 1:2000) for 15 min at RT. hMDMs were ﬁxed with
2% formaldehyde and lysed with Triton X-100 containing buffer. ASC was stained
using an AF488 or 647 labeled ASC antibody (TMS-1) and nuclei were
counterstained with Draq5 or DAPI. iMos were ﬁxed with 4% formaldehyde and
stained for ASC (2EI-7, F(ab’)2-AF647). Nuclei were counterstained using
HOECHST. Cells were imaged using a Zeiss Observer.Z1 epiﬂuorescence
microscope. Images were quantiﬁed using Fiji59 or CellProﬁler60 software.
FACS analysis of NLRP3 expression. HEK293-FlpIn TREx NLRP3 cell lines were
treated overnight with the indicated doses of doxycycline. The next morning HEKs
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were harvested and analyzed for their NLRP3-tagRFP expression levels. iMos were
harvested without pre-treatment and analyzed for NLRP3-mCitrine expression.
In silico approaches. Spliceport (http://spliceport.cbcb.umd.edu/) was used to
analyze the strength of the splice donor and acceptor sites of human NLRP337. The
number of exonic splice enhancer sites within the LRR exons of human NLRP3 was
assessed with RescueESE (http://hollywood.mit.edu/burgelab/rescue-ese/)61.
Physico-chemical characteristics of the (artiﬁcial) splice variants were calculated
using the ProtParam online tool (https://web.expasy.org/protparam/).
LRR exon structure analysis. LRR annotations for human proteins were per-
formed using the ensmbldb Bioconductor Package62. All known canonical tran-
scripts as deﬁned by UCSC (GRCh38) were queried for LRR domains annotated by
the SMART database, namely: SM00369, SM00370, SM00364, SM00367, SM00368,
and SM00365.
All exons spanning LRR domains were extracted for further analysis: exons
were divided into frame-preserving (divisible by 3) or frame-shifting and plotted
for their length distribution. Genes contributing to the major peaks within the exon
length distribution plot (69–75, 81–87, 141–147, and 168–174 bp) were identiﬁed
and used to create a phylogenetic tree: amino-acid sequences were aligned using
MUSCLE63 and the dist.ml function from the phangorn Bioconductor package64
was used with default settings to create a distance matrix that was then used to
estimate an un-rooted phylogenetic tree using the Neighbor Joining clustering
method.
RNASeq. hMDM were primed for 3 h with 2 ng/mL LPS. RNA was isolated and
RNA integrity was checked for every sample before library preparation using a
RNA ScreenTape on a Tapestation. RNA content of samples was quantiﬁed using a
Qubit device.
Total RNA of 2 µg were used as input material. The RNA Seq library was
generated using ‘SENSE mRNA-Seq Library Prep Kit V2’ (Lexogen) according to
the manufacturer’s recommendation with the following details: for reverse
transcription and ligation the RTL buffer was used to generate rather bigger
fragments. To further adjust the size of the library fragments, during the
puriﬁcation after second strand synthesis 14 µl PB and 2 µl PS were used. Before
library ampliﬁcation and adapter attachment, a test ampliﬁcation was performed.
The library was ampliﬁed over 12 cycles using the i7 index primers 7001, 7002,
7004, 7005, and 7007 to maintain the best possible color-balance during the ﬁrst
cycles of RNA Seq.
The fragment size of the generated library was controlled using a Tapestation
D1000 Screen Tape.
RNA sequencing was performed on an Illumine HiSeq high output ﬂow cell
using V4 chemistry in the Next Generation Sequencing (NGS) Core Facility of the
Medical Faculty of the University of Bonn. We aimed for a sequencing depth of
200M reads per sample (2×125 bp). RNA libraries from 5 donors were pooled and
distributed on 4 lanes.
RNA sequencing analysis. Sequencing reads were aligned to the human genome
(build GRCh38/hg38) using STAR aligner65 with default settings and transcript
annotations from Ensembl GRCh38.90: > STAR --runThreadN 3 --genomeDir
/genome/human/staridx_primary/ --sjdbGTFﬁle /annotation/Homo_sapiens.
GRCh38.90.chr.gtf --readFilesIn Donor*_1.fastq Donor*_2.fq --outSAMtype BAM
SortedByCoordinate
Transcript abundances for all samples were quantiﬁed using Kallisto66 with
default settings >kallisto quant -i Homo_sapiens.GRCh38.cdna.all.gene.kidx -o
$outdir -t 3 Donor*_1.fastq Donor*_2.fq
and then summarized to gene level abundances using the tximport
Bioconductor Package67.
Sashimi plots were generated using the sashimi_plot utility from the MISO
software68, and exon skipping events were quantiﬁed using MISO “exon-centric”
percentage-spliced-in analysis. Soft-clipped adapter sequence was removed from all
STAR aligned samples and reads were subsequently trimmed to a uniform length
of 91 bases per read, using in-house developed scripts. MISO was run with the
following command: > miso --run./index_dir/./bams/Donor*.sorted.bam --output-
dir miso_out --read-len 91.
Statistical analysis. Statistical analysis was performed using GraphPad Prism8, as
indicated in ﬁgure legends.
Ethics. Human primary cells were extracted from blood concentrates provided by
the blood donation service of the University Clinics Bonn (ERC Ethikantrag Lfd.
Nr. 184/16 “Activation and regulation of Inﬂammasomes (InﬂammAct)”. This
study has complied with all relevant ethical regulations for animal testing and
research.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
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